Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Inspira Technologies Oxy BHN ( (IINN) ) is now available.
On February 3, 2026, Inspira Technologies announced it has successfully validated its next-generation standalone HYLA blood sensor system in advanced blood labs, demonstrating 94.2% accuracy in continuous optical measurement of pCO₂ at a level consistent with clinical requirements. By decoupling HYLA from the company’s own life-support hardware and configuring it as a universal, standalone sensor that can integrate with existing operating room and ICU workflows, Inspira aims to tap into the roughly $50 billion global heart-lung surgery and extracorporeal procedures market, open a faster commercial route to the global installed base of perfusion systems, and support a high-margin recurring revenue model built on disposable sensors and modular software upgrades, while reinforcing its longer-term push into blood-based diagnostics.
The most recent analyst rating on (IINN) stock is a Sell with a $0.70 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.
The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support systems and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., while the in-development INSPIRA ART500 aims to provide oxygenation for awake, spontaneously breathing patients. The company is also advancing its HYLA proprietary blood sensor platform and positioning itself as a broader life-support and MedTech player through multiple cleared products, a growing IP portfolio and streamlined operations.
Average Trading Volume: 171,173
Technical Sentiment Signal: Strong Sell
Current Market Cap: $26.79M
See more data about IINN stock on TipRanks’ Stock Analysis page.